News

Retail chatter around GSK picked up on Thursday after Blenrep, one of its cancer drugs, hit a roadblock with U.S. regulators.
US FDA approves GSK’s Shingrix in a prefilled syringe presentation for prevention of shingles: London, UK Friday, July 18, 2025, 09:00 Hrs [IST] GSK plc announced that the US Fo ...
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...
GSK remains confident in Blenrep’s safety and efficacy, and will work with the FDA as it reviews the drug, the company said ...
The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...
The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as the agency’s Oncologic Drugs Advisory ...
The US Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) have launched investigations ...
GSK today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe formulation of its ...
GSK’s attempt to relaunch Blenrep was blocked by FDA advisers due to poor clinical benefit, safety concerns, and eye-related ...
The newly approved prefilled syringe version of Shingrix is expected to simplify administration and supports efforts to ...
The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...
On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...